HealthEquity, Inc.

Equities

HQY

US42226A1079

Software

Real-time Estimate Cboe BZX 12:57:24 2024-03-28 pm EDT 5-day change 1st Jan Change
81.36 USD +2.05% Intraday chart for HealthEquity, Inc. -0.94% +22.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jefferies Adjusts HealthEquity Price Target to $95 From $79, Maintains Buy Rating MT
Healthequity Insider Sold Shares Worth $2,694,731, According to a Recent SEC Filing MT
BTIG Research Adjusts HealthEquity Price Target to $110 From $100, Maintains Buy Rating MT
Stocks Edge Down Pre-Bell Ahead of Fed Policy Decision; Asia Up, Europe Falls MT
RBC Raises Price Target on HealthEquity to $92 From $90, Notes Fiscal Q4 Results at High End of Preannounced Ranges; Outperform Kept MT
HealthEquity Maintains Fiscal 2025 Revenue Outlook Following Fourth-Quarter Beat MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears DJ
HealthEquity's Fiscal Q4 Non-GAAP Earnings, Revenue Rise; Fiscal 2025 Guidance Issued MT
Transcript : HealthEquity, Inc., Q4 2024 Earnings Call, Mar 19, 2024
Earnings Flash (HQY) HEALTHEQUITY Reports Q4 EPS $0.63, vs. Street Est of $0.60 MT
Earnings Flash (HQY) HEALTHEQUITY Posts Q4 Revenue $262.4M, vs. Street Est of $259M MT
HealthEquity, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended January 31, 2024 CI
HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2025 CI
Stocks Down Marginally Pre-Bell Ahead of Fed Policy Meeting; Asia Churns, Europe Mostly Up MT
Barrington Raises PT on HealthEquity to $100 From $85, Expects Improving Operating and Financial Performance, Keeps Outperform Rating MT
Barclays Adjusts HealthEquity's Price Target to $104 From $84, Keeps Overweight Rating MT
Deutsche Bank Adjusts HealthEquity Price Target to $95 From $88, Maintains Buy Rating MT
RBC Raises Price Target on HealthEquity to $90 From $77, Keeps Outperform Rating MT
Transcript : HealthEquity, Inc. - Analyst/Investor Day
HealthEquity Updates Fiscal 2024 Outlook, Affirms 2025 Guidance MT
HealthEquity, Inc. Revises Earnings Guidance for the Fiscal Year Ended January 31, 2024 and Reaffirms Earnings Guidance for the Fiscal Year Ending January 31, 2025 CI
Transcript : HealthEquity, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM
Healthequity Insider Sold Shares Worth $2,857,721, According to a Recent SEC Filing MT
Healthequity Insider Sold Shares Worth $4,800,046, According to a Recent SEC Filing MT
Deutsche Bank Raises HealthEquity Price Target to $88 From $85, Maintains Buy Rating MT
Chart HealthEquity, Inc.
More charts
HealthEquity, Inc. is engaged in providing technology-enabled services that help consumers make healthcare savings and spending decisions. The Company uses its technology to manage consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It offers a mutual fund investment platform and access to an online-only automated investment advisory service to all its members. It offers multiple cloud-based platforms, accessed by its members online via a desktop or mobile device, through which individuals can make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings and make investment choices.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
79.72 USD
Average target price
96.09 USD
Spread / Average Target
+20.54%
Consensus
  1. Stock
  2. Equities
  3. Stock HealthEquity, Inc. - Nasdaq
  4. News HealthEquity, Inc.
  5. Baird Adjusts HealthEquity's Price Target to $53 from $86, Keeps Neutral Rating